8110 Stock Chart & Stats
€2.82
€0.16(5.13%)
At close: 4:00 PM EDT
€2.82
€0.16(5.13%)
Day’s Range― - ―
52-Week Range€2.08 - €6.75
Previous CloseN/A
Volume0.00
Average Volume (3M)317.00
Market Cap
€24.70M
Enterprise Value€161.59M
Total Cash (Recent Filing)€381.26M
Total Debt (Recent Filing)€281.98M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Nov 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.92
Shares Outstanding5,196,964
10 Day Avg. Volume0
30 Day Avg. Volume317
Financial Highlights & Ratios
PEG Ratio1.81
Price to Book (P/B)-0.22
Price to Sales (P/S)0.01
P/FCF Ratio1.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)€14.71B
Bulls Say, Bears Say
Bulls Say
Platform-led Business TransitionGrowth in marketplace service income supports a more scalable and less asset-intensive business model. If sustained, the platform transition can deepen engagement with pharmacies and healthcare partners while reducing reliance on lower-quality or underperforming operations.
Operating Cost DisciplineLower operating and fulfillment costs indicate that management is actively reshaping the cost base. Durable efficiency gains could improve the economics of the platform, help offset weak revenue conditions, and support progress toward stronger cash generation over time.
Promotional Product GrowthRapid growth in promotional pharmaceutical products demonstrates that 111 can use its digital platform to expand pharmacy distribution for selected offerings. Broader penetration and improved product economics could strengthen partner value and create a more productive revenue mix.
Bears Say
Revenue ContractionThe sharp revenue decline shows that the strategic reshaping is reducing the current scale of the business, even if management expects a leaner model. Lower volume can limit operating leverage and makes the company more dependent on successful growth in marketplace services.
Persistent Unprofitability And Thin MarginsOngoing losses and a thin gross margin leave limited room to absorb operating costs or commercial pressure. Until the company demonstrates consistent positive earnings, the business remains dependent on continued restructuring and improved mix to establish durable earnings power.
Weak Solvency And Renewed Cash BurnPersistently negative equity weakens financial flexibility, while the return to negative operating and free cash flow indicates that recent cash-generation improvements were not yet sustained. Together, these conditions can constrain investment capacity and increase funding pressure.
111 News
8110 FAQ
What was 111 Inc’s price range in the past 12 months?
111 Inc lowest stock price was €2.08 and its highest was €6.75 in the past 12 months.
What is 111 Inc’s market cap?
111 Inc’s market cap is €24.70M.
When is 111 Inc’s upcoming earnings report date?
111 Inc’s upcoming earnings report date is Nov 26, 2026 which is in 46 days.
How were 111 Inc’s earnings last quarter?
111 Inc released its earnings results on Sep 17, 2026. The company reported -€0.571 earnings per share for the quarter.
Is 111 Inc overvalued?
According to Wall Street analysts 111 Inc’s price is currently Overvalued.
Does 111 Inc pay dividends?
111 Inc does not currently pay dividends.
What is 111 Inc’s EPS estimate?
111 Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 111 Inc have?
111 Inc has 5,196,964 shares outstanding.
What happened to 111 Inc’s price movement after its last earnings report?
111 Inc reported an EPS of -€0.571 in its last earnings report. Following the earnings report the stock price went up 13.194%.
Which hedge fund is a major shareholder of 111 Inc?
Currently, no hedge funds are holding shares in DE:8110
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
111 Inc
Based in Shanghai, People's Republic of China, 111, Inc. (established in 2010 and formerly known as New Peak Group until April 2018) is a prominent entity in the Chinese healthcare sector, operating a comprehensive online-to-offline (O2O) ecosystem. Its operations are structured across both business-to-business (B2B) and business-to-consumer (B2C) channels. The company facilitates the sale of a wide array of medical and wellness products, reaching customers through its online retail channels as well as wholesale and retail pharmacy networks. This extensive product catalog encompasses prescription medications, over-the-counter drugs (both Western and traditional Chinese), dietary supplements like vitamins, optical products such as contact lenses, various medical supplies and devices (e.g., bandages, thermometers), personal care items (including skincare, birth control, and sexual wellness products), and infant care essentials. Beyond product sales, 111, Inc. provides value-added services to consumers, such as online consultation and electronic prescription fulfillment. For its business partners, the company manages an online marketplace enabling third-party vendors to directly supply pharmacies. It further supports its "1 Pharmacy" clients – comprising pharmacies and wholesalers – with online loan application services, alongside offering data and supply chain integration solutions. Its operational scope also extends to critical back-end functions, including warehousing, logistics management, procurement, research and development, consulting, as well as software development and IT support. As of December 31, 2021, its physical footprint included 14 retail pharmacies operating under the "Yi Hao Pharmacy" brand across several key regions: Guangzhou, Tianjin, Kunshan, Chongqing, and Wuhan. The company caters to a diverse clientele, encompassing individual consumers, pharmacies, pharmaceutical manufacturers and distributors, medical practitioners, and insurance providers.
Technical Analysis
Rockwell Med
―
Dyadic International
―
Rein Therapeutics
―
Elutia
―
Neuphoria Therapeutics
―









